TY - JOUR
T1 - The Effects of Lovastatin in Hyperlipidemic Patients With the Nephrotic Syndrome
AU - Kasiske, Bertram L.
AU - Velosa, Jorge A.
AU - Halstenson, Charles E.
AU - La Belle, Patrice
AU - Langendörfer, Alexandra
AU - Keane, William F.
PY - 1990
Y1 - 1990
N2 - Hypercholesterolemia may pose a substantial risk for cardiovascular disease. The present investigation was designed to evaluate the safety and efficacy of the cholesterol synthesis inhibitor, lovastatin, in 13 nephrotic patients with 5.6 ± 0.7 g/24 h of albuminuria. All patients were maintained on a low cholesterol diet throughout the study. After a 4-week placebo period, lovastatin was administered, 20 mg twice daily for 6 weeks. Lovastatin reduced total cholesterol by 27% from 8.6 ± 0.6 mmol/L (331 ± 24 mg/dL) to 6.3 ± 0.4 mmol/L (242 ± 17 mg/dL) (P < 0.01), low-density lipoprotein cholesterol by 27%, from 5.8 ± 0.5 mmol/L (223 ± 20 mg/dL) to 4.2 ± 0.6 mmol/L (163 ± 22 mg/dL) (P < 0.01), and apolipoprotein B by 29%, from 153 ± 12 mg/dL to 109 ± 8 mg/dL (P < 0.01). Triglycerides and very-low-density lipoprotein (VLDL) cholesterol levels were also reduced by 30% and 37%, respectively (P < 0.01). High-density lipoprotein (HDL) cholesterol, and apolipoproteins A-1 and A-2 were not significantly altered. Renal function and urine protein excretion were not affected by lovastatin. Although one patient developed diarrhea and discontinued treatment before completing 6 weeks of lovastatin, the other 12 patients had no adverse effects. In this short-term study, lovastatin therapy had few side effects and had favorable effects on the lipoprotein profile of nephrotic syndrome patients.
AB - Hypercholesterolemia may pose a substantial risk for cardiovascular disease. The present investigation was designed to evaluate the safety and efficacy of the cholesterol synthesis inhibitor, lovastatin, in 13 nephrotic patients with 5.6 ± 0.7 g/24 h of albuminuria. All patients were maintained on a low cholesterol diet throughout the study. After a 4-week placebo period, lovastatin was administered, 20 mg twice daily for 6 weeks. Lovastatin reduced total cholesterol by 27% from 8.6 ± 0.6 mmol/L (331 ± 24 mg/dL) to 6.3 ± 0.4 mmol/L (242 ± 17 mg/dL) (P < 0.01), low-density lipoprotein cholesterol by 27%, from 5.8 ± 0.5 mmol/L (223 ± 20 mg/dL) to 4.2 ± 0.6 mmol/L (163 ± 22 mg/dL) (P < 0.01), and apolipoprotein B by 29%, from 153 ± 12 mg/dL to 109 ± 8 mg/dL (P < 0.01). Triglycerides and very-low-density lipoprotein (VLDL) cholesterol levels were also reduced by 30% and 37%, respectively (P < 0.01). High-density lipoprotein (HDL) cholesterol, and apolipoproteins A-1 and A-2 were not significantly altered. Renal function and urine protein excretion were not affected by lovastatin. Although one patient developed diarrhea and discontinued treatment before completing 6 weeks of lovastatin, the other 12 patients had no adverse effects. In this short-term study, lovastatin therapy had few side effects and had favorable effects on the lipoprotein profile of nephrotic syndrome patients.
KW - Cholesterol
KW - apolipoproteins
KW - kidney disease
KW - lipoproteins
UR - http://www.scopus.com/inward/record.url?scp=0025075476&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025075476&partnerID=8YFLogxK
U2 - 10.1016/S0272-6386(12)80586-5
DO - 10.1016/S0272-6386(12)80586-5
M3 - Article
C2 - 2294737
AN - SCOPUS:0025075476
SN - 0272-6386
VL - 15
SP - 8
EP - 15
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 1
ER -